Russia’s sovereign wealth fund has said that it had signed a deal with South Korea’s GL Rapha for the biotechnology firm to produce over 150 million doses per year of the Sputnik V coronavirus vaccine.
The South Korean firm is expected to begin production next month, the Russian Direct Investment Fund (RDIF) said in a statement. The doses, produced in South Korea, will be intended for global distribution, it said.
